X4 Pharmaceuticals Inc

X4 Pharmaceuticals Inc

XFOR - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$394.75M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
X4 Pharmaceuticals IncX4 Pharmaceuticals Inc-4.7--58%--
$2.74

Current Fair Value

12.3% downside

Overvalued by 12.3% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$394.75 Million
Enterprise Value$210.08 Million
Earnings per Share$-1.87
Beta0.35
Outstanding Shares126,523,631

Return

Return on Equity-57.98%ROE
Return on Assets-34.73%
Return on Invested Capital-42.83%

Valuation & Multiples

P/E Ratio-4.66P/E Ratio
PEG14.44PEG
Price to Sales-Price to Sales
Price to Book Ratio3.12Price to Book Ratio
Enterprise Value to Revenue12.39
Enterprise Value to EBIT-2.26
Enterprise Value to Net Income-3
Total Debt to Enterprise0.01
Debt to Equity0.01Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 5, 2026
EPS
-$0.16
Est. -$0.17
Revenue
$2.90 M
Est. $2.78 M

Next Earnings Call

Expected Date
March 16, 2027
EPS Estimate
-$0.22
Consensus analyst estimate
Revenue Estimate
$2.76 M
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.00000%
Total Calls68,600▼ 86.29%
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %32.35%▼ 43.78%
Total Invested$118.54M▼ 73.61%
Investors Holding48▼ 43.00%

About X4 Pharmaceuticals Inc

72 employees

X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4 pathway, with a focus on rare di...

X4 Pharmaceuticals Insider Information FAQ

Stockcircle tracks 3 top investors with a current 13F position in X4 Pharmaceuticals. Holdings come from the latest quarterly 13F filings filed with the SEC.

In the latest 13F quarter on Stockcircle, 1 top investor increased or opened positions among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Stockcircle shows 1 open-market insider purchase and 4 open-market insider sales for X4 Pharmaceuticals in the last six months from SEC Form 4 reports by executives, directors, and other insiders.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.